PFG
45
3
VZ
50
3
NWS
66
-3
LRCX
43
-2
SYY
53
4
ORCL
65
-2
SYK
64
-4
ADBE
49
3
BSX
67
-3
CINF
53
2
KMB
39
2
LYB
39
2
UPS
60
9
HOG
35
2
EOG
58
2
RSG
71
3
DD
63
3
R
71
4
NTAP
67
-3
ADSK
70
2
PFG
45
3
VZ
50
3
NWS
66
-3
LRCX
43
-2
SYY
53
4
ORCL
65
-2
SYK
64
-4
ADBE
49
3
BSX
67
-3
CINF
53
2
KMB
39
2
LYB
39
2
UPS
60
9
HOG
35
2
EOG
58
2
RSG
71
3
DD
63
3
R
71
4
NTAP
67
-3
ADSK
70
2
Financhill
Back

Akebia Therapeutics 10K Form

Buy
63

AKBA
Akebia Therapeutics

Last Price:
1.87
Seasonality Move:
46.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $194.62M
Cash Flow: $-6.7M
Price / Cash Flow: 0
Annual Sales: $-0.24
Price / Book: 0

Profitability

EPS (TTM): -0.22680
Net Income (TTM): $-45.99M
Gross Margin: $120.47M
Return on Equity: 0%
Return on Assets: -20.36%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for AKBA is 61.90%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 51.50% of Gross Profit Margin.
  • The Research & Development expenses have been 32.41% of Revenue.
  • The Interest Expense is -11.62% of Operating Income.
  • The Net Earning history of AKBA is -26.68% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: -0.76
Current Ratio: 1.52
Quick Ratio: 1.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKBA Technical Analysis vs Fundamental Analysis

Buy
63
Akebia Therapeutics (AKBA) is a Buy

Is Akebia Therapeutics a Buy or a Sell?